This site uses cookies to improve your experience. By viewing our content, you are accepting the use of cookies. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country we will assume you are from the United States. View our privacy policy and terms of use.

Remove Contract Manufacturing Remove Hormones Remove Pharmacy Related Topics
Clinical Development Clinical Trials Trials Development Drugs Manufacturing Clinical Trials Production More Related Topics >
article thumbnail

Enzalutamide by Pfizer for Relapsed Multiple Myeloma: Likelihood of Approval

Pharmaceutical Technology

FEBRUARY 27, 2023

Enzalutamide is under development for the treatment of non-metastatic castration-resistant prostate cancer, prostate cancer in patients with non-metastatic biochemical recurrence in the EU, China and Asia, and also for metastatic hormone-sensitive prostate cancer in the U.S,

Hormones 113
Hormones Contract Manufacturing Manufacturing Development 113
article thumbnail

Enzalutamide by Pfizer for Myelofibrosis: Likelihood of Approval

Pharmaceutical Technology

FEBRUARY 27, 2023

Enzalutamide is under development for the treatment of non-metastatic castration-resistant prostate cancer, prostate cancer in patients with non-metastatic biochemical recurrence in the EU, China and Asia, and also for metastatic hormone-sensitive prostate cancer in the U.S,

Hormones 100
Hormones Contract Manufacturing Manufacturing Development 100
article thumbnail

Enzalutamide by Pfizer for Relapsed Chronic Lymphocytic Leukemia (CLL): Likelihood of Approval

Pharmaceutical Technology

FEBRUARY 27, 2023

Enzalutamide is under development for the treatment of non-metastatic castration-resistant prostate cancer, prostate cancer in patients with non-metastatic biochemical recurrence in the EU, China and Asia, and also for metastatic hormone-sensitive prostate cancer in the U.S,

Hormones 100
Hormones Contract Manufacturing Manufacturing Development 100
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

 

Stay Connected

Join 32,000+ Insiders by signing up for our newsletter

About
About
Editions
Editions
Topics
Powered by Aggregage | Terms and Conditions | Your California Rights and Privacy Policy
© Aggregage 2024